| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.841 | 0.005 | 0.841 | Toll-Like receptor 7 agonist | 0.807 0.005 DBMET02935 | ||
| 0.839 | 0.005 | 0.839 | Toll-Like receptor agonist | 0.802 0.005 DBMET02935 | ||
| 0.815 | 0.004 | 0.815 | Spasmolytic | 0.595 0.013 DBMET02935 | ||
| 0.795 | 0.003 | 0.795 | Histamine H1 receptor antagonist | 0.245 0.01 DBMET02935 | ||
| 0.611 | 0.004 | 0.611 | Antihistaminic | 0.24 0.015 DBMET02935 | ||
| 0.578 | 0.009 | 0.715 | HERG channel blocker | 0.715 0.005 DBMET02935 | DBMET02935 | |
| 0.566 | 0.004 | 0.566 | Histamine antagonist | 0.228 0.016 DBMET02935 | ||
| 0.56 | 0.009 | 0.661 | Potassium channel (Voltage-sensitive) blocker | 0.661 0.005 DBMET02935 | DBMET02935 | |
| 0.548 | 0.004 | 0.548 | Acetylcholine muscarinic antagonist | 0.451 0.004 DBMET02935 | ||
| 0.549 | 0.008 | 0.635 | Potassium channel blocker | 0.635 0.005 DBMET02935 | DBMET02935 | |
| 0.515 | 0.005 | 0.52 | Cholinergic antagonist | 0.52 0.005 DBMET02935 | DBMET02935 | |
| 0.508 | 0.005 | 0.515 | Acetylcholine antagonist | 0.515 0.005 DBMET02935 | DBMET02935 | |
| 0.493 | 0.005 | 0.493 | Antipruritic | 0.322 0.011 DBMET02935 | ||
| 0.488 | 0.004 | 0.488 | Acetylcholine M1 receptor antagonist | 0.396 0.005 DBMET02935 | ||
| 0.452 | 0.005 | 0.452 | Interleukin 4 antagonist | 0.449 0.005 DBMET02935 | ||
| 0.457 | 0.011 | 0.457 | P-glycoprotein inhibitor | 0.308 0.028 DBMET02935 | ||
| 0.474 | 0.04 | 0.474 | Immunosuppressant | 0.225 0.171 DBMET02935 | ||
| 0.415 | 0.003 | 0.415 | Acetylcholine M3 receptor antagonist | 0.365 0.003 DBMET02935 | ||
| 0.445 | 0.051 | 0.445 | Antiobesity | 0.233 0.173 DBMET02935 | ||
| 0.42 | 0.028 | 0.42 | Interleukin antagonist | |||
| 0.384 | 0.006 | 0.384 | Bronchodilator | 0.257 0.012 DBMET02935 | ||
| 0.424 | 0.066 | 0.436 | Calcium channel L-type activator | 0.436 0.058 DBMET02935 | DBMET02935 | |
| 0.461 | 0.105 | 0.461 | Antiinflammatory | |||
| 0.375 | 0.03 | 0.375 | Hypolipemic | |||
| 0.341 | 0.007 | 0.341 | Calcium channel blocker | 0.2 0.03 DBMET02935 | ||
| 0.415 | 0.083 | 0.415 | Cyclophilin D inhibitor | |||
| 0.334 | 0.004 | 0.334 | Interleukin 5 antagonist | 0.27 0.004 DBMET02935 | ||
| 0.364 | 0.068 | 0.364 | Vasodilator, peripheral | 0.325 0.085 DBMET02935 | ||
| 0.288 | 0.005 | 0.288 | Alpha 1 adrenoreceptor agonist | 0.108 0.015 DBMET02935 | ||
| 0.286 | 0.027 | 0.321 | Neuropeptide Y2 antagonist | 0.321 0.012 DBMET02935 | DBMET02935 | |
| 0.262 | 0.004 | 0.262 | Sphingomyelinase inhibitor | 0.206 0.009 DBMET02935 | ||
| 0.324 | 0.077 | 0.324 | Cholesterol antagonist | 0.209 0.157 DBMET02935 | ||
| 0.241 | 0.009 | 0.271 | Calcium antagonist | 0.271 0.006 DBMET02935 | DBMET02935 | |
| 0.232 | 0.005 | 0.232 | Adrenaline agonist | 0.184 0.008 DBMET02935 | ||
| 0.218 | 0.007 | 0.218 | Electron transport complex I inhibitor | |||
| 0.208 | 0.006 | 0.208 | Acetylcholine M2 receptor antagonist | 0.158 0.01 DBMET02935 | ||
| 0.201 | 0.005 | 0.201 | Acetylcholine M5 receptor antagonist | 0.147 0.008 DBMET02935 | ||
| 0.201 | 0.008 | 0.201 | Interleukin 2 antagonist | |||
| 0.246 | 0.054 | 0.246 | Peptidyltransferase inhibitor | |||
| 0.247 | 0.06 | 0.385 | Psychostimulant | 0.385 0.025 DBMET02935 | DBMET02935 | |
| 0.192 | 0.006 | 0.192 | Calcium channel L-type blocker | 0.143 0.011 DBMET02935 | ||
| 0.183 | 0.01 | 0.183 | Alpha adrenoreceptor agonist | 0.174 0.012 DBMET02935 | ||
| 0.192 | 0.02 | 0.203 | Alpha 2c adrenoreceptor antagonist | 0.203 0.017 DBMET02935 | DBMET02935 | |
| 0.26 | 0.092 | 0.321 | Hypoxia-inducible factor 1 alpha inhibitor | 0.321 0.056 DBMET02935 | DBMET02935 | |
| 0.182 | 0.014 | 0.182 | Sphingosine 1-phosphate receptor 2 antagonist | 0.121 0.094 DBMET02935 | ||
| 0.192 | 0.034 | 0.192 | Anesthetic local | |||
| 0.174 | 0.02 | 0.174 | Mediator release inhibitor | 0.107 0.061 DBMET02935 | ||
| 0.249 | 0.101 | 0.249 | Lipoxygenase inhibitor | |||
| 0.17 | 0.025 | 0.17 | Calcium channel (voltage-sensitive) blocker | 0.141 0.039 DBMET02935 | ||
| 0.226 | 0.084 | 0.226 | Platelet antagonist | |||
| 0.173 | 0.034 | 0.173 | Cholesterol synthesis inhibitor | 0.105 0.08 DBMET02935 | ||
| 0.256 | 0.122 | 0.256 | Sodium/bile acid cotransporter inhibitor | 0.212 0.172 DBMET02935 | ||
| 0.227 | 0.097 | 0.295 | Interleukin agonist | 0.295 0.05 DBMET02935 | DBMET02935 | |
| 0.245 | 0.125 | 0.247 | Interleukin 2 agonist | 0.247 0.121 DBMET02935 | DBMET02935 | |
| 0.161 | 0.045 | 0.163 | Sphingosine 1-phosphate receptor 5 antagonist | 0.163 0.042 DBMET02935 | DBMET02935 | |
| 0.161 | 0.047 | 0.192 | Adenylate cyclase stimulant | 0.192 0.018 DBMET02935 | DBMET02935 | |
| 0.195 | 0.084 | 0.213 | Platelet aggregation inhibitor | 0.213 0.072 DBMET02935 | DBMET02935 | |
| 0.244 | 0.14 | 0.244 | Vasodilator, coronary | 0.237 0.148 DBMET02935 | ||
| 0.201 | 0.099 | 0.201 | Antiamyloidogenic | |||
| 0.138 | 0.043 | 0.155 | Ferrochelatase inhibitor | 0.155 0.036 DBMET02935 | DBMET02935 | |
| 0.122 | 0.029 | 0.122 | Alpha 1b adrenoreceptor antagonist | 0.088 0.041 DBMET02935 | ||
| 0.156 | 0.065 | 0.249 | Lipid peroxidase inhibitor | 0.249 0.027 DBMET02935 | DBMET02935 | |
| 0.209 | 0.119 | 0.415 | Tyrosine 3 hydroxylase inhibitor | 0.415 0.007 DBMET02935 | DBMET02935 | |
| 0.106 | 0.017 | 0.15 | Dopamine uptake inhibitor | 0.15 0.01 DBMET02935 | DBMET02935 | |
| 0.11 | 0.022 | 0.16 | Acetylcholine M4 receptor antagonist | 0.16 0.009 DBMET02935 | DBMET02935 | |
| 0.109 | 0.021 | 0.109 | Leukotriene synthesis inhibitor | 0.108 0.022 DBMET02935 | ||
| 0.108 | 0.021 | 0.108 | Alpha 1d adrenoreceptor antagonist | 0.061 0.04 DBMET02935 | ||
| 0.241 | 0.158 | 0.331 | Calcium channel activator | 0.331 0.064 DBMET02935 | DBMET02935 | |
| 0.089 | 0.011 | 0.089 | Oleamide hydrolase inhibitor | 0.057 0.022 DBMET02935 | ||
| 0.142 | 0.065 | 0.161 | Ca2+-transporting ATPase inhibitor | 0.161 0.023 DBMET02935 | DBMET02935 | |
| 0.083 | 0.008 | 0.083 | Beta 2 adrenoreceptor agonist | 0.082 0.008 DBMET02935 | ||
| 0.125 | 0.055 | 0.208 | 5 Hydroxytryptamine 2 antagonist | 0.208 0.028 DBMET02935 | DBMET02935 | |
| 0.174 | 0.105 | 0.186 | Neurotrophic factor enhancer | 0.186 0.092 DBMET02935 | DBMET02935 | |
| 0.115 | 0.048 | 0.115 | Antiadrenergic | |||
| 0.178 | 0.113 | 0.381 | Cyclic AMP phosphodiesterase inhibitor | 0.381 0.019 DBMET02935 | DBMET02935 | |
| 0.112 | 0.047 | 0.112 | Adrenaline antagonist | |||
| 0.218 | 0.156 | 0.251 | Antithrombotic | 0.251 0.125 DBMET02935 | DBMET02935 | |
| 0.083 | 0.025 | 0.083 | Prostaglandin EP2 antagonist | |||
| 0.079 | 0.021 | 0.079 | Sigma receptor antagonist | |||
| 0.062 | 0.005 | 0.062 | Prostaglandin D2 agonist | |||
| 0.087 | 0.03 | 0.128 | Dopamine D1 antagonist | 0.128 0.018 DBMET02935 | DBMET02935 | |
| 0.06 | 0.005 | 0.06 | Leukotriene B4 receptor 1 antagonist | |||
| 0.118 | 0.063 | 0.167 | 5 Hydroxytryptamine 2B antagonist | 0.167 0.034 DBMET02935 | DBMET02935 | |
| 0.068 | 0.015 | 0.068 | Dopamine D5 antagonist | |||
| 0.096 | 0.049 | 0.169 | 5 Hydroxytryptamine 2A antagonist | 0.169 0.024 DBMET02935 | DBMET02935 | |
| 0.13 | 0.083 | 0.13 | Farnesoid X receptor antagonist | |||
| 0.078 | 0.036 | 0.078 | Peroxisome proliferator-activated receptor gamma antagonist | |||
| 0.074 | 0.036 | 0.074 | Leukotriene antagonist | |||
| 0.15 | 0.114 | 0.168 | Anesthetic general | 0.168 0.096 DBMET02935 | DBMET02935 | |
| 0.047 | 0.011 | 0.047 | Prostaglandin agonist | |||
| 0.062 | 0.026 | 0.062 | Leukotriene B4 antagonist | |||
| 0.038 | 0.005 | 0.038 | Leukotriene B4 receptor 2 antagonist | |||
| 0.041 | 0.008 | 0.041 | Prostaglandin EP2 agonist | |||
| 0.098 | 0.066 | 0.105 | Anabolic | 0.105 0.056 DBMET02935 | DBMET02935 | |
| 0.059 | 0.027 | 0.059 | CC chemokine 5 receptor antagonist | 0.054 0.032 DBMET02935 | ||
| 0.059 | 0.028 | 0.073 | Alpha-mannosidase inhibitor | 0.073 0.015 DBMET02935 | DBMET02935 | |
| 0.053 | 0.022 | 0.069 | Mannosidase inhibitor | 0.069 0.012 DBMET02935 | DBMET02935 | |
| 0.048 | 0.021 | 0.052 | Beta adrenoreceptor agonist | 0.052 0.014 DBMET02935 | DBMET02935 | |
| 0.04 | 0.017 | 0.04 | Ceramide glucosyltransferase inhibitor | 0.034 0.028 DBMET02935 | ||
| 0.095 | 0.072 | 0.095 | Nav1.1 sodium channel blocker | |||
| 0.032 | 0.01 | 0.032 | Prostaglandin E2 agonist | |||
| 0.076 | 0.055 | 0.076 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.14 | 0.121 | 0.163 | Lipocortins synthesis antagonist | 0.163 0.088 DBMET02935 | DBMET02935 | |
| 0.075 | 0.056 | 0.075 | CC chemokine receptor antagonist | |||
| 0.042 | 0.023 | 0.082 | GABA uptake inhibitor | 0.082 0.005 DBMET02935 | DBMET02935 | |
| 0.136 | 0.118 | 0.136 | Amyloid beta precursor protein antagonist | |||
| 0.086 | 0.07 | 0.246 | HIV-1 integrase (Overall Integration) inhibitor | 0.246 0.005 DBMET02935 | DBMET02935 | |
| 0.152 | 0.137 | 0.247 | Aldehyde oxidase inhibitor | 0.247 0.083 DBMET02935 | DBMET02935 | |
| 0.06 | 0.045 | 0.165 | Adrenaline uptake inhibitor | 0.165 0.008 DBMET02935 | DBMET02935 | |
| 0.08 | 0.067 | 0.08 | Ornithine decarboxylase inhibitor | |||
| 0.065 | 0.054 | 0.065 | MDM2 inhibitor | |||
| 0.058 | 0.051 | 0.09 | DNA gyrase inhibitor | 0.09 0.021 DBMET02935 | DBMET02935 | |
| 0.012 | 0.006 | 0.012 | Thromboxane agonist | |||
| 0.091 | 0.087 | 0.149 | 5 Hydroxytryptamine antagonist | 0.149 0.05 DBMET02935 | DBMET02935 | |
| 0.129 | 0.126 | 0.139 | Amyloid beta aggregation inhibitor | 0.139 0.117 DBMET02935 | DBMET02935 | |
| 0.118 | 0.117 | 0.118 | Sigma receptor agonist | |||
| 0.057 | 0.061 | 0.076 | Interferon inducer | 0.076 0.028 DBMET02935 | DBMET02935 | |
| 0.121 | 0.127 | 0.133 | Pregnane X receptor agonist | 0.133 0.091 DBMET02935 | DBMET02935 | |
| 0.12 | 0.127 | 0.184 | Arachidonic acid antagonist | 0.184 0.049 DBMET02935 | DBMET02935 | |
| 0.081 | 0.089 | 0.113 | Lanosterol 14 alpha demethylase inhibitor | 0.113 0.038 DBMET02935 | DBMET02935 | |
| 0.049 | 0.058 | 0.073 | 5 Hydroxytryptamine uptake inhibitor | 0.073 0.037 DBMET02935 | DBMET02935 | |
| 0.067 | 0.077 | 0.089 | Interferon agonist | 0.089 0.039 DBMET02935 | DBMET02935 | |
| 0.08 | 0.101 | 0.092 | Bile acid receptor antagonist | 0.092 0.067 DBMET02935 | DBMET02935 | |
| 0.033 | 0.058 | 0.052 | Kainate receptor agonist | 0.052 0.012 DBMET02935 | DBMET02935 | |
| 0.028 | 0.057 | 0.041 | Membrane dipeptidase inhibitor | 0.041 0.025 DBMET02935 | DBMET02935 | |
| 0.064 | 0.094 | 0.105 | Viral attachment inhibitor | 0.105 0.02 DBMET02935 | DBMET02935 | |
| 0.07 | 0.1 | 0.165 | Prolactin inhibitor | 0.165 0.017 DBMET02935 | DBMET02935 | |
| 0.03 | 0.06 | 0.052 | NMDA 2A receptor antagonist | 0.052 0.036 DBMET02935 | DBMET02935 | |
| 0.072 | 0.103 | 0.099 | CC chemokine 5 receptor agonist | 0.099 0.022 DBMET02935 | DBMET02935 | |
| 0.115 | 0.148 | 0.138 | Interferon gamma antagonist | 0.138 0.096 DBMET02935 | DBMET02935 | |
| 0.042 | 0.076 | 0.087 | NMDA 2C receptor antagonist | 0.087 0.021 DBMET02935 | DBMET02935 | |
| 0.072 | 0.106 | 0.111 | Gastric antisecretory | 0.111 0.052 DBMET02935 | DBMET02935 | |
| 0.046 | 0.082 | 0.054 | Pregnane X receptor antagonist | 0.054 0.048 DBMET02935 | DBMET02935 | |
| 0.075 | 0.117 | 0.105 | Adenylate cyclase inhibitor | 0.105 0.08 DBMET02935 | DBMET02935 | |
| 0.055 | 0.098 | 0.108 | Glycine receptor agonist | 0.108 0.017 DBMET02935 | DBMET02935 | |
| 0.061 | 0.108 | 0.23 | Neuropeptide Y antagonist | 0.23 0.011 DBMET02935 | DBMET02935 | |
| 0.03 | 0.079 | 0.044 | Integrin alpha1beta1 antagonist | 0.044 0.014 DBMET02935 | DBMET02935 | |
| 0.056 | 0.106 | 0.152 | Alpha 2 adrenoreceptor antagonist | 0.152 0.027 DBMET02935 | DBMET02935 | |
| 0.012 | 0.062 | 0.057 | Arginase inhibitor | 0.057 0.011 DBMET02935 | DBMET02935 | |
| 0.022 | 0.074 | 0.032 | Carboxypeptidase B inhibitor | 0.032 0.025 DBMET02935 | DBMET02935 | |
| 0.074 | 0.128 | 0.094 | Mucolytic | 0.094 0.087 DBMET02935 | DBMET02935 | |
| 0.05 | 0.107 | 0.091 | Phospholipase D inhibitor | 0.091 0.021 DBMET02935 | DBMET02935 | |
| 0.033 | 0.092 | 0.086 | Aconitate hydratase inhibitor | 0.086 0.012 DBMET02935 | DBMET02935 | |
| 0.026 | 0.088 | 0.077 | Aromatase inhibitor | 0.077 0.029 DBMET02935 | DBMET02935 | |
| 0.026 | 0.089 | 0.05 | Dopamine transporter inhibitor | 0.05 0.032 DBMET02935 | DBMET02935 | |
| 0.002 | 0.066 | 0.008 | Integrin alpha5beta6 antagonist | 0.008 0.004 DBMET02935 | DBMET02935 | |
| 0.078 | 0.144 | 0.266 | Alpha-N-acetylglucosaminidase inhibitor | 0.266 0.02 DBMET02935 | DBMET02935 | |
| 0.032 | 0.102 | 0.072 | Carbamoyl phosphate synthetase inhibitor | 0.072 0.033 DBMET02935 | DBMET02935 | |
| 0.118 | 0.19 | 0.185 | Phospholipase C inhibitor | 0.185 0.056 DBMET02935 | DBMET02935 | |
| 0.048 | 0.121 | 0.112 | 5 Hydroxytryptamine 2C antagonist | 0.112 0.039 DBMET02935 | DBMET02935 | |
| 0.085 | 0.16 | 0.152 | Protein kinase stimulant | 0.152 0.067 DBMET02935 | DBMET02935 | |
| 0.102 | 0.179 | 0.138 | Melanin inhibitor | 0.138 0.1 DBMET02935 | DBMET02935 | |
| 0.094 | 0.172 | 0.128 | Vanilloid 1 agonist | 0.128 0.071 DBMET02935 | DBMET02935 | |
| 0.044 | 0.122 | 0.081 | Ryanodine receptor antagonist | 0.081 0.008 DBMET02935 | DBMET02935 | |
| 0.042 | 0.121 | 0.085 | Aminopeptidase I inhibitor | 0.085 0.038 DBMET02935 | DBMET02935 | |
| 0.04 | 0.121 | 0.066 | Glutamate decarboxylase inhibitor | 0.066 0.06 DBMET02935 | DBMET02935 | |
| 0.056 | 0.138 | 0.101 | GABA B receptor agonist | 0.101 0.016 DBMET02935 | DBMET02935 | |
| 0.048 | 0.131 | 0.085 | Glutamate (mGluR6) antagonist | 0.085 0.02 DBMET02935 | DBMET02935 | |
| 0.059 | 0.146 | 0.57 | GABA C receptor agonist | 0.57 0.003 DBMET02935 | DBMET02935 | |
| 0.058 | 0.148 | 0.118 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.118 0.04 DBMET02935 | DBMET02935 | |
| 0.044 | 0.14 | 0.069 | Somatostatin 1 agonist | 0.069 0.066 DBMET02935 | DBMET02935 | |
| 0.094 | 0.193 | 0.142 | Papain-like protease (SARS coronavirus) inhibitor | 0.142 0.042 DBMET02935 | DBMET02935 | |
| 0.068 | 0.18 | 0.105 | Cyclooxygenase 3 inhibitor | 0.105 0.096 DBMET02935 | DBMET02935 | |
| 0.054 | 0.166 | 0.11 | Triose-phosphate isomerase inhibitor | 0.11 0.039 DBMET02935 | DBMET02935 | |
| 0.03 | 0.147 | 0.078 | Phenylalanine 4-hydroxylase inhibitor | 0.078 0.039 DBMET02935 | DBMET02935 | |
| 0.025 | 0.146 | 0.051 | Farnesyltransferase inhibitor | 0.051 0.026 DBMET02935 | DBMET02935 | |
| 0.016 | 0.138 | 0.029 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.029 0.013 DBMET02935 | DBMET02935 | |
| 0.111 | 0.233 | 0.199 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.199 0.074 DBMET02935 | DBMET02935 | |
| 0.008 | 0.131 | 0.044 | Lysine carboxypeptidase inhibitor | 0.044 0.009 DBMET02935 | DBMET02935 | |
| 0.121 | 0.245 | 0.271 | Superoxide dismutase inhibitor | 0.271 0.063 DBMET02935 | DBMET02935 | |
| 0.025 | 0.152 | 0.048 | Glucose-6-phosphate isomerase inhibitor | 0.048 0.033 DBMET02935 | DBMET02935 | |
| 0.037 | 0.167 | 0.077 | NMDA receptor antagonist | 0.077 0.069 DBMET02935 | DBMET02935 | |
| 0.012 | 0.145 | 0.037 | NMDA receptor subunit 3A antagonist | 0.037 0.027 DBMET02935 | DBMET02935 | |
| 0.059 | 0.193 | 0.081 | Estrogen-related receptor beta agonist | 0.081 0.063 DBMET02935 | DBMET02935 | |
| 0.06 | 0.199 | 0.1 | Microtubule formation inhibitor | 0.1 0.092 DBMET02935 | DBMET02935 | |
| 0.029 | 0.169 | 0.098 | Na+ K+ transporting ATPase inhibitor | 0.098 0.034 DBMET02935 | DBMET02935 | |
| 0.011 | 0.155 | 0.044 | Epoxide hydrolase 1 inhibitor | 0.044 0.008 DBMET02935 | DBMET02935 | |
| 0.184 | 0.338 | 0.325 | 5 Hydroxytryptamine release inhibitor | 0.325 0.139 DBMET02935 | DBMET02935 | |
| 0.036 | 0.191 | 0.079 | Glutamate dehydrogenase inhibitor | 0.079 0.046 DBMET02935 | DBMET02935 | |
| 0.058 | 0.212 | 0.099 | 3C-Like protease (SARS coronavirus) inhibitor | 0.099 0.034 DBMET02935 | DBMET02935 | |
| 0.024 | 0.184 | 0.058 | Carbonic anhydrase stimulant | 0.058 0.043 DBMET02935 | DBMET02935 | |
| 0.02 | 0.181 | 0.075 | Phosphofructokinase-1 inhibitor | 0.075 0.044 DBMET02935 | DBMET02935 | |
| 0.06 | 0.222 | 0.131 | Nav1.5 sodium channel blocker | 0.131 0.042 DBMET02935 | DBMET02935 | |
| 0.115 | 0.285 | 0.256 | Gastrin inhibitor | 0.256 0.073 DBMET02935 | DBMET02935 | |
| 0.017 | 0.188 | 0.066 | Argininosuccinate synthase inhibitor | 0.066 0.033 DBMET02935 | DBMET02935 | |
| 0.019 | 0.19 | 0.041 | Thymidine kinase inhibitor | 0.041 0.028 DBMET02935 | DBMET02935 | |
| 0.092 | 0.264 | 0.173 | Succinate dehydrogenase inhibitor | 0.173 0.076 DBMET02935 | DBMET02935 | |
| 0.04 | 0.215 | 0.097 | Creatine kinase inhibitor | 0.097 0.062 DBMET02935 | DBMET02935 | |
| 0.012 | 0.192 | 0.109 | Dopamine D5 agonist | 0.109 0.004 DBMET02935 | DBMET02935 | |
| 0.031 | 0.213 | 0.072 | Acetylcholine M3 receptor agonist | 0.072 0.069 DBMET02935 | DBMET02935 | |
| 0.058 | 0.241 | 0.097 | Adenylate kinase inhibitor | 0.097 0.073 DBMET02935 | DBMET02935 | |
| 0.044 | 0.239 | 0.277 | GABA C receptor antagonist | 0.277 0.005 DBMET02935 | DBMET02935 | |
| 0.032 | 0.228 | 0.106 | Glycine receptor antagonist | 0.106 0.027 DBMET02935 | DBMET02935 | |
| 0.105 | 0.302 | 0.68 | 5 Hydroxytryptamine release stimulant | 0.68 0.008 DBMET02935 | DBMET02935 | |
| 0.018 | 0.219 | 0.038 | Glutamate (mGluR8) agonist | 0.038 0.027 DBMET02935 | DBMET02935 | |
| 0.033 | 0.235 | 0.102 | Aminopeptidase B inhibitor | 0.102 0.063 DBMET02935 | DBMET02935 | |
| 0.009 | 0.211 | 0.056 | Guanylate cyclase inhibitor | 0.056 0.015 DBMET02935 | DBMET02935 | |
| 0.017 | 0.223 | 0.062 | Biliverdin reductase inhibitor | 0.062 0.039 DBMET02935 | DBMET02935 | |
| 0.008 | 0.218 | 0.036 | Calcium-sensing receptor agonist | 0.036 0.009 DBMET02935 | DBMET02935 | |
| 0.136 | 0.35 | 0.467 | 5 Hydroxytryptamine uptake stimulant | 0.467 0.005 DBMET02935 | DBMET02935 | |
| 0.013 | 0.229 | 0.045 | NMDA receptor subunit 3B antagonist | 0.045 0.03 DBMET02935 | DBMET02935 | |
| 0.014 | 0.237 | 0.055 | Alcohol oxidase inhibitor | 0.055 0.04 DBMET02935 | DBMET02935 | |
| 0.021 | 0.245 | 0.101 | Acetylcholine nicotinic antagonist | 0.101 0.039 DBMET02935 | DBMET02935 | |
| 0.011 | 0.236 | 0.026 | Thymidine phosphorylase inhibitor | 0.026 0.018 DBMET02935 | DBMET02935 | |
| 0.014 | 0.24 | 0.044 | Sphingosine kinase 1 inhibitor | 0.044 0.023 DBMET02935 | DBMET02935 | |
| 0.024 | 0.256 | 0.085 | Nicotinic alpha3beta2 receptor antagonist | 0.085 0.011 DBMET02935 | DBMET02935 | |
| 0.05 | 0.283 | 0.091 | Phosphodiesterase 6D inhibitor | 0.091 0.073 DBMET02935 | DBMET02935 | |
| 0.018 | 0.253 | 0.066 | Androgen agonist | 0.066 0.034 DBMET02935 | DBMET02935 | |
| 0.096 | 0.334 | 0.24 | DNA synthesis inhibitor | 0.24 0.073 DBMET02935 | DBMET02935 | |
| 0.013 | 0.254 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.026 DBMET02935 | DBMET02935 | |
| 0.005 | 0.249 | 0.066 | Acetylcholine M1 receptor agonist | 0.066 0.02 DBMET02935 | DBMET02935 | |
| 0.017 | 0.263 | 0.11 | Nicotinic alpha4beta2 receptor antagonist | 0.11 0.024 DBMET02935 | DBMET02935 | |
| 0.025 | 0.277 | 0.077 | GABA aminotransferase inhibitor | 0.077 0.05 DBMET02935 | DBMET02935 | |
| 0.018 | 0.275 | 0.066 | Sphingosine kinase inhibitor | 0.066 0.03 DBMET02935 | DBMET02935 | |
| 0.025 | 0.284 | 0.054 | Glucosylceramidase inhibitor | 0.054 0.039 DBMET02935 | DBMET02935 | |
| 0.039 | 0.303 | 0.184 | Cytidine deaminase inhibitor | 0.184 0.055 DBMET02935 | DBMET02935 | |
| 0.015 | 0.279 | 0.062 | Phenylethanolamine N methyltransferase inhibitor | 0.062 0.007 DBMET02935 | DBMET02935 | |
| 0.013 | 0.278 | 0.039 | Nicotinic receptor alpha3 subunit antagonist | 0.039 0.038 DBMET02935 | DBMET02935 | |
| 0.073 | 0.346 | 0.22 | 5 Hydroxytryptamine 1E antagonist | 0.22 0.108 DBMET02935 | DBMET02935 | |
| 0.005 | 0.279 | 0.032 | Kainate receptor 2 antagonist | 0.032 0.028 DBMET02935 | DBMET02935 | |
| 0.043 | 0.329 | 0.151 | Toll-Like receptor 2 antagonist | 0.151 0.052 DBMET02935 | DBMET02935 | |
| 0.048 | 0.334 | 0.161 | Peroxidase inhibitor | 0.161 0.072 DBMET02935 | DBMET02935 | |
| 0.045 | 0.335 | 0.089 | Glutamate (mGluR7) agonist | 0.089 0.085 DBMET02935 | DBMET02935 | |
| 0.015 | 0.31 | 0.068 | Porphobilinogen synthase inhibitor | 0.068 0.058 DBMET02935 | DBMET02935 | |
| 0.009 | 0.305 | 0.024 | Glutamate (mGluR1) agonist | 0.024 0.019 DBMET02935 | DBMET02935 | |
| 0.042 | 0.34 | 0.103 | DOPA decarboxylase inhibitor | 0.103 0.071 DBMET02935 | DBMET02935 | |
| 0.036 | 0.341 | 0.091 | NADH dehydrogenase inhibitor | 0.091 0.055 DBMET02935 | DBMET02935 | |
| 0.008 | 0.313 | 0.07 | Acetylcholine muscarinic agonist | 0.07 0.027 DBMET02935 | DBMET02935 | |
| 0.007 | 0.32 | 0.041 | Alpha 1d adrenoreceptor agonist | 0.041 0.024 DBMET02935 | DBMET02935 | |
| 0.134 | 0.452 | 0.316 | Caspase 9 stimulant | 0.316 0.177 DBMET02935 | DBMET02935 | |
| 0.015 | 0.34 | 0.051 | Sphingosine kinase 2 inhibitor | 0.051 0.045 DBMET02935 | DBMET02935 | |
| 0.153 | 0.493 | 0.368 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.368 0.131 DBMET02935 | DBMET02935 | |
| 0.009 | 0.375 | 0.027 | Estrogen-related receptor gamma antagonist | 0.027 0.024 DBMET02935 | DBMET02935 | |
| 0.011 | 0.379 | 0.026 | Hedgehog signaling activator | 0.026 0.024 DBMET02935 | DBMET02935 | |
| 0.005 | 0.376 | 0.028 | Nicotinic acid receptor 2 antagonist | 0.028 0.016 DBMET02935 | DBMET02935 | |
| 0.03 | 0.403 | 0.073 | Vanilloid 4 agonist | 0.073 0.057 DBMET02935 | DBMET02935 | |
| 0.007 | 0.381 | 0.05 | Nicotinic receptor alpha7 subunit antagonist | 0.05 0.043 DBMET02935 | DBMET02935 | |
| 0.022 | 0.397 | 0.095 | Cystathionine beta-synthase inhibitor | 0.095 0.082 DBMET02935 | DBMET02935 | |
| 0.017 | 0.392 | 0.064 | Protease 3C (Human rhinovirus) inhibitor | 0.064 0.045 DBMET02935 | DBMET02935 | |
| 0.015 | 0.392 | 0.061 | NMDA receptor agonist | 0.061 0.046 DBMET02935 | DBMET02935 | |
| 0.019 | 0.399 | 0.061 | Dihydroorotate oxidase inhibitor | 0.061 0.027 DBMET02935 | DBMET02935 | |
| 0.026 | 0.414 | 0.186 | GABA C receptor rho-1 antagonist | 0.186 0.01 DBMET02935 | DBMET02935 | |
| 0.012 | 0.412 | 0.075 | Protein kinase C beta inhibitor | 0.075 0.038 DBMET02935 | DBMET02935 | |
| 0.072 | 0.482 | 0.269 | RNA-directed DNA polymerase inhibitor | 0.269 0.04 DBMET02935 | DBMET02935 | |
| 0.009 | 0.421 | 0.044 | GABA B receptor antagonist | 0.044 0.028 DBMET02935 | DBMET02935 | |
| 0.017 | 0.431 | 0.096 | Falcipain 3 inhibitor | 0.096 0.075 DBMET02935 | DBMET02935 | |
| 0.022 | 0.437 | 0.107 | UDP-glucose 4-epimerase inhibitor | 0.107 0.054 DBMET02935 | DBMET02935 | |
| 0.05 | 0.467 | 0.15 | ATPase inhibitor | 0.15 0.102 DBMET02935 | DBMET02935 | |
| 0.067 | 0.494 | 0.151 | Neurotensin receptor agonist | 0.151 0.099 DBMET02935 | DBMET02935 | |
| 0.045 | 0.477 | 0.242 | 12-Lipoxygenase inhibitor | 0.242 0.114 DBMET02935 | DBMET02935 | |
| 0.077 | 0.509 | 0.303 | GABA C receptor rho-3 antagonist | 0.303 0.113 DBMET02935 | DBMET02935 | |
| 0.006 | 0.443 | 0.068 | 5 Hydroxytryptamine 6 antagonist | 0.068 0.031 DBMET02935 | DBMET02935 | |
| 0.006 | 0.466 | 0.058 | Neuronal nicotinic receptor antagonist | 0.058 0.056 DBMET02935 | DBMET02935 | |
| 0.025 | 0.5 | 0.105 | MAP kinase kinase 7 inhibitor | 0.105 0.009 DBMET02935 | DBMET02935 | |
| 0.009 | 0.489 | 0.05 | Histamine H4 receptor antagonist | 0.05 0.03 DBMET02935 | DBMET02935 | |
| 0.03 | 0.52 | 0.124 | Neuropeptide Y1 antagonist | 0.124 0.113 DBMET02935 | DBMET02935 | |
| 0.005 | 0.499 | 0.052 | Nicotinic receptor alpha4 subunit antagonist | 0.052 0.03 DBMET02935 | DBMET02935 | |
| 0.009 | 0.505 | 0.097 | Acetylcholine agonist | 0.097 0.049 DBMET02935 | DBMET02935 | |
| 0.022 | 0.521 | 0.096 | Electrolyte absorption antagonist | 0.096 0.064 DBMET02935 | DBMET02935 | |
| 0.003 | 0.513 | 0.024 | Imidazoline I1 receptor antagonist | 0.024 0.011 DBMET02935 | DBMET02935 | |
| 0.013 | 0.524 | 0.067 | 5 Hydroxytryptamine 3 agonist | 0.067 0.038 DBMET02935 | DBMET02935 | |
| 0.033 | 0.548 | 0.17 | GABA C receptor rho-2 antagonist | 0.17 0.051 DBMET02935 | DBMET02935 | |
| 0.023 | 0.552 | 0.08 | Granulocyte macrophage colony stimulating factor agonist | 0.08 0.075 DBMET02935 | DBMET02935 | |
| 0.005 | 0.553 | 0.042 | Histamine H1 receptor agonist | 0.042 0.034 DBMET02935 | DBMET02935 | |
| 0.006 | 0.559 | 0.067 | Alpha 2 adrenoreceptor agonist | 0.067 0.034 DBMET02935 | DBMET02935 | |
| 0.072 | 0.628 | 0.199 | Nitric-oxide synthase stimulant | 0.199 0.091 DBMET02935 | DBMET02935 | |
| 0.015 | 0.572 | 0.103 | 5 Hydroxytryptamine 3A agonist | 0.103 0.073 DBMET02935 | DBMET02935 | |
| 0.049 | 0.61 | 0.26 | Insulysin inhibitor | 0.26 0.088 DBMET02935 | DBMET02935 | |
| 0.014 | 0.591 | 0.091 | Potassium channel (Ca-activated) activator | 0.091 0.063 DBMET02935 | DBMET02935 | |
| 0.083 | 0.674 | 0.196 | 5 Hydroxytryptamine 3E antagonist | 0.196 0.07 DBMET02935 | DBMET02935 | |
| 0.004 | 0.614 | 0.072 | 5 Hydroxytryptamine 2A agonist | 0.072 0.034 DBMET02935 | DBMET02935 | |
| 0.091 | 0.712 | 0.258 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.258 0.056 DBMET02935 | DBMET02935 | |
| 0.016 | 0.646 | 0.106 | Interleukin 8 antagonist | 0.106 0.083 DBMET02935 | DBMET02935 | |
| 0.03 | 0.663 | 0.131 | CF transmembrane conductance regulator agonist | 0.131 0.115 DBMET02935 | DBMET02935 | |
| 0.001 | 0.636 | 0.017 | Nicotinic alpha4 receptor agonist | 0.017 0.01 DBMET02935 | DBMET02935 | |
| 0.005 | 0.641 | 0.082 | Acetylcholine nicotinic agonist | 0.082 0.054 DBMET02935 | DBMET02935 | |
| 0.001 | 0.64 | 0.02 | Cyclin T1 inhibitor | 0.02 0.01 DBMET02935 | DBMET02935 | |
| 0.002 | 0.645 | 0.043 | Nicotinic alpha3beta4 receptor agonist | 0.043 0.008 DBMET02935 | DBMET02935 | |
| 0.005 | 0.652 | 0.052 | 5 Hydroxytryptamine 2B agonist | 0.052 0.012 DBMET02935 | DBMET02935 | |
| 0.005 | 0.66 | 0.083 | Protein kinase C zeta inhibitor | 0.083 0.08 DBMET02935 | DBMET02935 | |
| 0.002 | 0.659 | 0.036 | Nicotinic alpha4beta2 receptor agonist | 0.036 0.01 DBMET02935 | DBMET02935 | |
| 0.005 | 0.67 | 0.036 | Integrin alpha2 antagonist | 0.036 0.027 DBMET02935 | DBMET02935 | |
| 0.008 | 0.716 | 0.057 | Myc inhibitor | 0.057 0.033 DBMET02935 | DBMET02935 | |
| 0.002 | 0.733 | 0.045 | 5 Hydroxytryptamine 2 agonist | 0.045 0.044 DBMET02935 | DBMET02935 | |
| 0.019 | 0.752 | 0.141 | 3C-like protease (Human coronavirus) inhibitor | 0.141 0.117 DBMET02935 | DBMET02935 | |
| 0.005 | 0.784 | 0.066 | Lysine-specific demethylase 1A inhibitor | 0.066 0.021 DBMET02935 | DBMET02935 | |
| 0.003 | 0.825 | 0.091 | 5 Hydroxytryptamine 2C agonist | 0.091 0.009 DBMET02935 | DBMET02935 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |